Syndax Pharmaceuticals, Inc. (SNDX)
NASDAQ: SNDX · Real-Time Price · USD
20.32
+0.58 (2.94%)
At close: Dec 5, 2025, 4:00 PM EST
20.90
+0.58 (2.85%)
After-hours: Dec 5, 2025, 7:09 PM EST
Syndax Pharmaceuticals Employees
Syndax Pharmaceuticals had 270 employees as of December 31, 2024. The number of employees increased by 86 or 46.74% compared to the previous year.
Employees
270
Change (1Y)
86
Growth (1Y)
46.74%
Revenue / Employee
$412,237
Profits / Employee
-$1,153,989
Market Cap
1.77B
Employees Chart
Related Stocks
| Company Name | Employees |
|---|---|
| UnitedHealth Group | 400,000 |
| Johnson & Johnson | 138,100 |
| Thermo Fisher Scientific | 125,000 |
| Abbott Laboratories | 114,000 |
| AstraZeneca | 92,900 |
| Novo Nordisk | 77,349 |
| Novartis AG | 75,883 |
| Merck & Co. | 75,000 |
SNDX News
- 2 days ago - Syndax Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) - GlobeNewsWire
- 4 days ago - Syndax Announces Participation at the 8th Annual Evercore Healthcare Conference - GlobeNewsWire
- 6 days ago - Syndax: Early Commercial Momentum Points Toward Strong 2026 Growth - Seeking Alpha
- 25 days ago - Syndax Pharmaceuticals, Inc. (SNDX) Presents at UBS Global Healthcare Conference 2025 Transcript - Seeking Alpha
- 4 weeks ago - Syndax Pharmaceuticals: Thesis Firing On All Cylinders, Sales Acceleration In 2026 - Seeking Alpha
- 4 weeks ago - Syndax Pharmaceuticals, Inc. (SNDX) Q3 2025 Earnings Call Transcript - Seeking Alpha
- 4 weeks ago - Syndax Reports Third Quarter 2025 Financial Results and Provides Business Update - GlobeNewsWire
- 4 weeks ago - Syndax Announces Compelling Revuforj® (revumenib) and Niktimvo™ (axatilimab-csfr) Data Accepted for Presentation at ASH 2025 - GlobeNewsWire